olipudase alfa (GZ402665)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sphingomyelin Lipidosis
Conditions
Sphingomyelin Lipidosis
Trial Timeline
— → —
NCT ID
NCT04877132About olipudase alfa (GZ402665)
olipudase alfa (GZ402665) is a pre-clinical stage product being developed by Sanofi for Sphingomyelin Lipidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04877132. Target conditions include Sphingomyelin Lipidosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04877132 | Pre-clinical | Completed |
Competing Products
6 competing products in Sphingomyelin Lipidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| Olipudase alfa | Sanofi | Pre-clinical | 22 |
| placebo (saline) + Olipudase alfa | Sanofi | Phase 2/3 | 64 |
| GZ402665 | Sanofi | Phase 2 | 51 |
| Olipudase alfa | Sanofi | Phase 1/2 | 40 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 32 |